Dr Dionysis Papadatos-Pastos
Dr. Papadatos-Pastos is a distinguished oncologist specialising in lung cancer, mesothelioma, thymoma, and thymic cancer. With an extensive publication record in leading medical journals, he is a sought-after speaker and contributor to national and international conferences. Dr. Papadatos-Pastos adopts a multidisciplinary approach to deliver personalised and comprehensive care for his patients.
Bio
Dr Dionysis Papadatos-Pastos is a highly experienced thoracic oncologist with over 20 years of expertise in lung cancer, mesothelioma, thymoma, and thymic cancer. He is committed to combining medical excellence with compassionate, patient-centred care.
Dr. Papadatos-Pastos graduated in medicine from the University of Athens with distinction, which was followed by his PhD in medical oncology (focusing on biomarkers) in 2012 with First Class honours. He trained in medical oncology at top UK cancer centres and completed a fellowship at the Royal Marsden’s phase I clinical trials unit. His work focused on advancing targeted therapies and immunotherapy combinations for non-small cell lung cancer, small cell lung cancer, and mesothelioma. He was awarded a diploma in medical oncology from the Institute of Cancer Research at the University of London.
He leads the lung cancer program at the CRUK UCL Clinical Trials Centre and co-chairs the London Clinic Lung Cancer MDT, where he develops individualised treatment plans through a multidisciplinary approach.
Dr Papadatos-Pastos is an avid researcher and has been the principal investigator on multiple academic and commercial clinical trials. In 2010 he received the ASCO Merit Award. His research, which is published in leading journals, emphasises personalised treatment strategies using immunotherapy and targeted approaches.
He has also presented at conferences, nationally and worldwide. His topics of research include the development of novel targeted therapies for the treatment of lung cancer, and assessing combinations of immunotherapy drugs with other anti-cancer compounds.
Outside work, he mentors junior doctors, enjoys swimming, and values time with his family.
Areas of expertise
- Non-small cell lung cancer
- Small cell lung cancer
- Mesothelioma
- Thymoma
- Thymic cancer
More information
146 Harley Street
London, W1G 7JL
- ASCO Merit Award 2010
- Qualified 2002
- National and Kapodistrian University of Athens 1995-2002
- Consultant in Medical Oncology
University College London Hospitals - Consultant in Medical Oncology
The Princess Alexandra Hospital
Articles
Article: Living with Purpose: Lynda’s Journey with Cancer
Research
As the Principal Investigator of the HyPeR clinical trial (NIHR UCLH Clinical Research Facility), Dr Papadatos-Pastos leads efforts to understand and overcome resistance to immunotherapy in lung cancer. The trial is investigating the mechanisms behind immunotherapy resistance and explores whether adding a novel drug to immunotherapy can reverse this resistance and improve outcomes. Early results have been encouraging, demonstrating potential to enhance treatment response. These findings have been published in a respected oncology journal, highlighting the trial’s clinical significance. Dr Papadatos-Pastos continues to oversee patient enrolment, treatment protocols, and data analysis, aiming to refine and expand immunotherapy options for lung cancer patients.
- RCP
- MDU
Dr Papadatos-Pastos has been featured in print publications such as The Guardian, The Evening Standard and Cosmopolitan UK.
